纤维蛋白原、纤维蛋白及其降解产物对共培养血管内皮细胞纤溶活性的影响

目的研究纤维蛋白原（Fg）、纤维蛋白（Fb）及其降解产物（FDP）对共培养体系中人脐静脉内皮细胞组织型纤溶酶原激活物和纤溶酶原激活物抑制剂表达的影响。方法应用Transwell膜建立人脐静脉内皮细胞-兔主动脉平滑肌细胞共培养体系，在不同浓度（0、0．5、1．5、3．0、4．5和6．0g／L）Fg、Fb和FDP干预24h后，分别检测该共培养体系中人脐静脉内皮细胞组织型纤溶酶原激活物和纤溶酶原激活物抑制剂mRNA水平（RT-PCR法）以及培养上清中组织型纤溶酶原激活物和纤溶酶原激活物抑制剂抗原含量（ELISA法）与活性（发色底物法）的变化情况。结果Fg对组织型纤溶酶原激活物的表达没有显著影响，较高浓度的Fg（3．0～4．5g／L）可明显促进纤溶酶原激活物抑制剂mRNA表达、抗原含量及活性升高，但过高浓度的Fg（6．0g／L）却抑制纤溶酶原激活物抑制剂的表达。3．0-4．5g／L的Fb对组织型纤溶酶原激活物mRNA和抗原含量都起上调作用，同时显著下调组织型纤溶酶原激活物活性。较高浓度的Fb（1．5-4．5g／L）则可明显上调纤溶酶原激活物抑制剂的表达，且在mRNA、蛋白和活性水平趋势基本一致。3．0-6．0g／L的FDP均可明显下调组织型纤溶酶原激活物mRNA、蛋白和活性水平，1．5-6．0mg／ml的FDP均可促进纤溶酶原激活物抑制剂的高表达。结论Fg、Fb和FDP可以通过影响组织型纤溶酶原激活物和纤溶酶原激活物抑制剂的表达，引起纤溶活性降低，参与动脉粥样硬化的发展进程。     

ACS患者血浆vWF和PAI-1水平与冠状动脉狭窄的相关性研究

目的探讨血浆假性血友病因子(vWF)、组织型纤溶酶原激活物抑制物(PAI-1)水平与冠状动脉狭窄的相关性。方法测定58例急性冠脉综合征(ACS)患者vWF和PAI-1含量,按造影结果分为单支病变与多支病变组,Gensini法计算冠脉造影积分。结果多支病变组与单支病变组的vWF水平分别为(160.39±35.07)%与(134.06±24.91)%,PAI-1水平分别为66.42 ng/mL±14.10 ng/mL与54.30 ng/mL±10.32 ng/mL,两组比较差异有统计学意义(P0.05);vWF、PAI-1水平与冠脉病变数及积分有明显相关性。结论 vWF,PAI-1水平与急性冠脉综合征患者冠状动脉狭窄相关。     

血管紧张素Ⅱ及缬沙坦对培养人脐静脉内皮细胞产生纤溶因子的影响

目的 探讨血管紧张素Ⅱ（angiotensinⅡ,AngⅡ）对内皮细胞纤溶功能的影响及缬沙坦的干预作用。方法用酶消化法收集并培养人脐静脉内皮细胞（human umbilical vein endothelial cells,HUVECs）,将10^-6,10^-7,10^-8,10^-9mol／L AngⅡ分别与HUVECs共同孵育12h;10^-7 mol／L AngⅡ和HUVECs分别孵育0,2,6,12,24,48h;10^-7 mol／L AngⅡ和10^-5,10^-6,10^-7,10^-8 mol／L缬沙坦（与HUVECs孵育12h;10^-6 mol／L缬沙坦与HUVECs孵育12h）。用酶联免疫吸附法测定上清液中组织型纤溶酶原激活物（tissue plasminogen activator,tPA）和1型纤溶酶原激活物抑制剂（plasminogen activator inhibitor-1,PAI-1）抗原浓度。结果 AngⅡ呈浓度依赖性升高HUVECs的PAI-1水平,最大效应浓度10^-7 mol／L;10^-7 mol／LAngⅡ对HUVECs作用,孵育2h PAI-1含量即升高,12h达高峰（198μg／L）;缬沙坦呈浓度依赖性降低AngⅡ促HUVECs分泌PAI-1,缬沙坦最大效应浓度10^-6mol／L;AngⅡ和缬沙坦对HUVECs分泌tPA没有明显影响。结论 AngⅡ通过促进HUVECs分泌PAI-1而降低纤溶活性;缬沙坦通过抑制AngⅡ的促PAI-1分泌作用而提高纤溶活性,提示有助于动脉粥样硬化血栓性疾病的防治。     

罗格列酮减轻糖基化终末产物对大鼠肾系膜细胞PAI-1的影响

目的观察过氧化物酶体增殖体激活受体γ（PPAR-γ）激活剂罗格列酮对糖基化终末产物（AGEs）诱导的大鼠肾系膜细胞纤溶酶原激活物抑制剂1（PAI-1）变化的影响。方法ELISA测定PAI-1蛋白含量，底物发色法检测纤溶酶原激活物（PA）活性，酶谱法分析基质金属蛋白酶（MMPs）活性。结果AGEs（25-200mg／L）可不同程度上调系膜细胞PAI-1表达，降低PA活性，给予罗格列酮（2．5～10mmol／L）可减轻AGEs（100mg／L）引起的PAI-1表达上调，并增加PA和MMP-2活性。结论罗格列酮减轻AGEs引起的PAI-1表达增加，提高PA和MMP-2的活性。     

2型糖尿病纤溶系统变化与胰岛素抵抗的关系

目的探讨2型糖尿病患者纤溶活性变化与胰岛素抵抗之间的关系。方法采用酶联免疫吸附法测定63例2型糖尿病患者（包括无血管并发症组30例和有血管并发症组33例）和25例正常对照者血浆组织型纤溶酶原激活剂（t-PA）、纤溶酶原激活物抑制剂-1（PAI-1）含量,结合临床资料分析其变化趋势及影响因素。结果2型糖尿病患者血浆t-PA含量明显降低（P〈0．01）,而PAI-1含量明显升高（P〈0．01）,合并血管病变者,此变化更为显著（均P〈0．001）。多元逐步回归分析显示,HOMA模型胰岛素抵抗指数（HOMA—IR）是PAI-1升高的独立危险因素。结论2型糖尿病患者纤溶活性降低,胰岛素抵抗在降低其纤溶活性,并发血管病变中起了重要作用。     

长球囊血管成形术对糖尿病足凝血及纤溶功能的影响

目的：观察长球囊血管成形术治疗糖尿病足术后凝血和纤溶系统活性的动态变化，探讨长球囊血管成形术预防再狭窄的可能机制。方法：选取糖尿病足患者40例，实验组20例，行长球囊血管成形术，对照组20例行短球囊血管成形术，术前，术后即刻、术后24h采取股静脉血，检测组织型纤溶酶原激活物（t—PA）、纤溶酶原激活物抑制剂（PAI-1）、纤维蛋白肽A（FPA）的含量。结果：两组患者的t—PA含量在术后即刻均降低，术后24h实验组的较术后即刻有明显恢复（P〈0．05），且较对照组的显著（P〈0．05），两组分别为（33．30±3．20）ng／ml，（31．01±0．89）ng／ml。PAI-1含量术后两组均显著升高（P〈0．05），24h两组患者均显著降低，实验组降低更显著（P〈0．05），两组分别为（44．33±0．75）ng／ml，（47．86±2．52）ng／ml。FPA含量术后两组均显著升高（P〈0．05），24h两组均显著降低，实验组降低更显著（P〈0．05）。结论：手术前、后t—PA、PAI-1、FPA含量的变化．提示长球囊血管成形术对糖尿病足治疗有效，可能降低血栓事件发生，预防术后再狭窄。     

焦虑或抑郁情绪对原发性高血压患者血栓前状态的影响

目的：观察焦虑或抑郁情绪对原发性高血压患者血栓前状态的影响。方法：112高血压病患者被均分为高血压合并焦虑或抑郁组（EH＋A／D组）和单纯高血压组（EH组）,测定两组病人血清CD62P、血管假性血友病因子（vWF）、组织型纤溶酶原激活剂（t．PA）、组织型纤溶酶原激活剂抑制剂（PAI-1）、内皮素（ET）．1等血栓前状态指标水平。结果：与EH组比较,EH＋A／D组CD62P[（4．52±2．01）％比（8．38±1．96）％]、vWF[（155．28±23．11）％比（185．23±22．21）％]、PAI-1[（54．35±13．21）ng／L比（79．88±14．53）ng／L]、ET-1r（121．56±33．32）ng／L比（152．78±30．23）ng／L]水平明显升高（P均〈0．05）,而t-PA[（19．37土11．46）ng／L比（9．56±8．32）ng／L]水平明显降低（P〈0．05）。结论：焦虑或抑郁情绪会通过激活血小板、影响血管内皮功能及纤溶系统的失衡,加重原发性高血压患者血栓前状态。     

HDL-C、PAI-1与多支血管病变的急性心肌梗死患者近期预后的关系

目的研究高密度脂蛋白胆固醇（HDL—C）、组织纤溶酶原激活物抑制物1（PAI-1）与多支血管病变的急性心肌梗死患者近期预后的关系并探讨其机制。方法选择2005—2007年因患急性ST段抬高型心肌梗死（STEMI）在我院心内科住院的129例患者。入选患者急诊冠脉造影证实合并2支或2支以上冠状动脉主支血管病变并接受直接PCI（pPCI）治疗。根据PCI术后30d的随访结果分成2组，发生主要心血管事件（MACE）组与无主要心血管事件组。入选患者均于入院后立即抽取静脉血测定PAI-1水平，入院次日清晨空腹抽取静脉血测定HDL—C水平，并分析HDL—C、PAI-1与STEMI患者近期预后关系及两者的相关性。结果发生心血管事件组HDL—C水平明显低于无心血管事件发生组[（0．87±0．15）mmol／L比（1．14±0．24）mmol／L，P〈0．01]，而PAI-1水平显著高于无心血管事件组[（62．84±20．65）U／ml比L（43．67±19．15）U／ml，P〈0．01]。多因素Logistic回归分析显示，血浆HDL—C水平（P〈0．01）和PAI-1水平（P=0．013）与多支血管病变的STEMI患者直接PCI后30d内MACE的发生独立相关。Pearson相关分析显示，发生MACE患者血浆HDL—C水平与PAI-1水平存在负相关（相关系数r=-0．344，P〈0．05）。结论血浆HDL—C、PAI-1水平的高低影响多支血管病变的STEMI患者直接PCI后的近期预后，HDL—C的促纤溶作用可能是影响预后的机制之一。     

纤溶酶原激活物抑制剂活性及其4G/5G基因多态性与急性冠状动脉综合征发病的关系

目的了解急性冠状动脉综合征患者血浆纤溶酶原激活物抑制剂1活性变化及其启动子4G/5G基因多态性特点,以探讨血浆纤溶酶原激活物抑制剂1及其基因多态性在急性冠状动脉综合征发病过程中的作用。方法对106例急性冠状动脉综合征患者9、8例稳定型冠心病患者和60例对照者用聚丙烯酰胺凝胶电泳寡核苷酸杂交分析法测定白细胞启动子4G/5G多态性位点的基因型,用酶联免疫吸附法测定血浆纤溶酶原激活物抑制剂1活性。结果急性冠状动脉综合征组血浆纤溶酶原激活物抑制剂1活性(18.0±2.9 kAU/L)较稳定型冠心病组(16.8±2.7 kAU/L)和对照组(16.2±2.8 kAU/L)增高(P<0.01和P<0.005);急性冠状动脉综合征组中4G/4G纯合子个体(49.1%)较稳定型冠心病组(28.6%)和对照组(26.7%)频率高(P<0.05);4G/4G纯合子个体的血浆纤溶酶原激活物抑制剂1活性最高,5G/5G个体最少(P<0.05)。结论血浆纤溶酶原激活物抑制剂1活性与启动子4G/5G基因型有关;血浆纤溶酶原激活物抑制剂1活性增高是急性冠状动脉综合征发病的危险因素之一。     

同型半胱氨酸对人脐静脉内皮细胞纤溶系统的影响

目的探讨同型半胱氨酸（homocysteine,Hcy）对血管内皮细胞纤溶系统影响。方法（1）将体外培养的人脐静脉血管内皮细胞（HUVEC）分为10个实验组（0、10、50、200、500μmol／L Hcy组及叶酸和上述各Hcy点共同培养组）,培养24h后,酶联免疫吸附实验法（ELISA）测定各组细胞上清液中纤溶酶原激活剂（plasminogen activator,tPA）及纤溶酶原激活物抑制剂1（plasminogen activator inhibitor1,PAI-1）抗原含量,逆转录聚合酶链反应分析（RT-PCR）法分析各组tPA及PAI-1的mRNA表达水平。（2）急性心肌梗死（AMI）患者53例及健康对照组48例,ELISA测定空腹血浆tPA及PAI-1含量,高效液相色谱法测定血浆Hcy水平。结果（1）500μmoL／L Hcy组PAI-1抗原及mRNA表达水平均明显增高（P〈0．05）。（2）以单纯培养基为对照组,生理浓度Hcy组内皮细胞tPA抗原合成及mRNA表达明显增高（P〈0．05）,而以10μmoL／L Hcy组为对照组时,500μmoL／L Hcy组tPA抗原合成及mRNA表达水平则明显减少（P〈0．05）。（3）500μmoL／L Hcy与叶酸共同培养组和单纯Hcy组相比,可以明显提高内皮细胞tPA抗原的合成及mRNA表达,减少PAI-1抗原合成及mRNA表达（P〈0、05）。（4）AMI组Hcy、tPA及PAI-1均明显高于健康对照组（P〈0．05）。结论在体外细胞时,超生理浓度Hcy可以通过下调tPA、上调PAI-1的mRNA表达,减少内皮细胞tPA抗原的分泌及增加PAI-1抗原的合成,可能降低纤溶系统的活性。叶酸则可以减少Hcy引起内皮细胞纤溶系统的损害,起到保护作用。Hcy是AMI的一个独立危险因素。     

Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction

Several studies have demonstrated an increased level of plasma plasminogen activator inhibitor-1 (PAI-1) in patients with coronary artery disease (CAD). However, the concentration of PAI-1 in platelets, which accounts for more than 90% of the blood PAI-1, is unknown in these patients. The present study evaluated the concentrations of PAI-1 and several fibrinolytic factors in the plasma and platelets of patients with CAD and the serial changes in patients with acute myocardial infarction (AMI). All 72 subjects had coronary angiography and were divided into 3 groups: CAD(-) group without coronary artery stenosis or myocardial ischemia (n=20), CAD(+) group with either stable angina pectoris (n=18) or old myocardial infarction (n=12) with coronary artery stenosis, and the AMI group admitted within 24h of symptom onset who underwent successful percutaneous transluminal coronary angioplasty (n=22). The concentrations of plasma PAI-1, tissue plasminogen activator (t-PA), and t-PA x PAI-1 complex were similar in the CAD(-) and CAD(+) groups, but were greater on day 1 in the AMI group compared with the 2 CAD groups. There were no significant differences between the 3 groups in the plasma concentrations of thrombin antithrombin III complex (TAT), alpha2-plasmin inhibitor-plasmin complex (PIC), beta-thromboglobulin (beta-TG), and platelet factor 4 (PF-4). The platelet PAI-1 concentrations did not differ between the CAD(-) and CAD(+) groups, but was greater on day 1 in the AMI group compared to the CAD groups. The platelet beta-TG and PF-4 were similar between the 3 groups. In the AMI group, both the plasma and platelet PAI-1 concentrations were greater on day 1, but the plasma PAI-1 rapidly decreased by day 5 and remained low on day 28 compared with day 1. The platelet PAI-1 concentration gradually decreased by day 5 and was further decreased by day 28. The serial changes of the plasma t-PA and t-PA PAI-1 complex during the course of AMI were similar to those of the plasma PAI-1. A positive correlation was found between the plasma and platelet PAI-1 in all 72 patients, but not in the AMI group alone. These results suggest that the PAI-1 that has accumulated in platelets at the onset of AMI might be released in large amounts into the plasma, resulting in an increase in thrombus formation.     

吸烟与冠心病关系的研究

目的 探讨吸烟与冠心病的发病及预后之间的关系.方法 将DESIRE-plus(Drug-E-luting Stent Impact on Revascularization plus)研究中符合本研究的3 186例患者分为三组,无吸烟组1 714例,已戒烟组462例,在吸烟组1 010例.通过分析三组间一般临床情况、冠状动脉造影和血运重建情况以及主要不良心脑血管事件发生率等方面的异同,探讨吸烟与冠心病的发病及预后之间的关系.结果 无吸烟组、已戒烟组、在吸烟组三组间年龄、诊断差异有统计学意义,年龄分别为62.5±9.8岁、60.5±9.9岁和55.3±10.3岁(P<0.001);在吸烟组ST段抬高心肌梗死及非ST段抬高心肌梗死的发生率分别为23.0%、5.7%,明显高于无吸烟组(13.1%、4.9%)、已戒烟组(12.3%、3.0%),P<0.001.冠状动脉造影情况也有明显差别,已戒烟组中三支病变及左主干病变分别占45.4%、10.6%,明显高于无吸烟组(39.2%、8.5%)和在吸烟组(35.2%、6.5%),P值分别为0.006和0.024.已戒烟组CABG率(33.8%)明显高于无吸烟组(29.0%)和在吸烟组(24.5%),P=0.001.三组间随访死亡率及总死亡率有明显差别,无吸烟组、已戒烟组、在吸烟组随访死亡率分别为1.6%、3.9%、1.3%(P=0.001),总死亡率分别为1.6%、3.9%、1.3%(P=0.001).结论 吸烟能使冠心病患者发病年龄提前,能促发血脂异常、炎性反应,从而引发冠心病,并有增加主要不良心脑血管事件发生率、随访死亡率、总死亡率的趋势.     

老年女性冠心病相关因素分析

目的探讨老年女性冠心病患者患病相关因素分析。方法选择临床诊断为可疑冠心病的老年女性患者139例,根据冠状动脉造影结果分为冠心病组(71例)和对照组(68例),观察年龄、体重、吸烟、停经时间、血尿酸水平、血压、血脂、糖尿病、骨质疏松与冠心病的相关性,进一步分析其相关的危险因素。结果冠心病组与对照组在肥胖、吸烟、过早停经、血尿酸增高、高血压、高脂血症、糖尿病、骨质疏松方面差异有统计学意义(P0.01);年龄在2组间的分布差异无统计学意义(P0.05)。老年女性冠心病的危险因素是糖尿病和骨质疏松。结论冠心病是一种多因素疾病,对于老年女性而言,糖尿病、骨质疏松可能是其发病的危险因素;吸烟、高血压、高脂血症、过早停经、肥胖、血尿酸增高等因素可能与其发病有关。     

The 4G/5G promotor polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients

BACKGROUND: Instent restenosis remains a significant clinical problem. Identification of patients at risk for instent restenosis may allow selection of individualized appropriate therapeutic approaches. Genetic polymorphisms have been suggested to be associated with the risk of instent restenosis. Smoking is known to influence hemostatic parameters. HYPOTHESIS: This study investigated the influence of the 4G/5G promotor polymorphism of the plasminogen activator inhibitor type I (PAI-1) gene on instent restenosis in smoking and nonsmoking patients. METHODS: In all, 300 consecutive patients (133 nonsmoking; 167 smoking) with elective coronary stent placement and 6-month angiographic follow-up were studied. Quantitative coronary angiography and genotyping with polymerase chain reaction analysis were performed in all patients. RESULTS: Nonsmoking PAI-1 4G/4G carriers showed a significantly greater late lumen loss (n = 38; 0.54 +/- 0.53 mm) compared with nonsmoking PAI-1 4G/5G (n = 68; 0.38 +/- 0.45 mm) or 5G/5G (n = 27; 0.19 +/- 0.23 mm) carriers, analysis of variance (ANOVA) p < 0.001. Smoking patients with the genotypes 4G/4G (n = 46; 0.53 +/- 0.54 mm) and 4G/5G (n = 79; 0.37 +/- 0.41 mm) had a late loss similar to that of nonsmoking patients. Smoking 5G/5G carriers had the highest late loss of all smoking patients (n = 42; 0.63 +/- 0.50); ANOVA p < 0.05; nonsmoking 5G/5G vs. smoking 5G/5G p < 0.001. CONCLUSION: The promotor polymorphism of the PAI-1 gene has a significant influence on instent restenosis after coronary stent implantation. The 5G/5G genotype predisposes nonsmoking gene carriers to less late lumen loss, whereas in smoking gene carriers this genotype is associated with the greatest late lumen loss. This might be explained by an altered expression pattern of hemostatic parameters.     

Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease

As depressed fibrinolysis is implicated in the pathogenesis of coronary artery disease, we have studied the activation of fibrinolysis during maximal, symptom-limited exercise in a group of 68 men. After exercise they were divided, according to their coronary angiography and exercise 201Tl emission computed tomography results, into three groups. Group 1: persons with normal exercise 201Tl emission computed tomography results and no underlying diseases who served as controls; group 2: patients with coronary artery disease without exercise-induced myocardial ischemia, and group 3: patients with coronary artery disease with transient, exercise-induced myocardial ischemia. Before and at peak exercise we measured the plasminogen activator activity (PAA) in the euglobulin fraction of plasma by an amidolytic method and the concentrations of tissue plasminogen activator (t-PA), activator-inhibitor complex - plasminogen activator inhibitor 1 (PAI-1) complexed with t-PA - and total PAI-1 by enzyme immunoassay. The concentration of free PAI-1 in plasma was calculated by subtraction of the concentration of activator-inhibitor complex from that of total PAI-1. Under basal conditions, group 3 had significantly higher free and total PAI-1 levels than group 1. There were no statistically significant differences between the three groups in PAA, t-PA, and activator-inhibitor complex levels. At peak exercise, group 1 showed the highest release of t-PA accompanied with highest increases in PAA as well as in activator-inhibitor complex, the proportion of released t-PA antigen not bound to PAI-1 being highest in group 1. Free PAI-1 decreased significantly, but there were no differences between individual groups.(ABSTRACT TRUNCATED AT 250 WORDS)     

冠心病患者血尿酸、高敏C反应蛋白检测的临床意义

目的：观察冠心病患者血清尿酸（UA）、高敏C反应蛋白（hs-CRP）含量的变化及临床意义。方法：96例冠心病患者根据冠脉造影结果分为单支病变组（30例）、双支病变组（50例）和三支病变组（16例）,测定其UA、hs-CRP水平,并且与42例冠脉造影正常的胸痛患者（正常对照组）比较。结果：与正常对照组的UA含量（329.81±42.25）mmol/L,hs-CRP含量（2.69±0.81）mg/L相比,冠心病组的UA、hs-CRP含量均明显增加（P均〈0.001）,且随着病变支数的增加（单支,双支,三支病变）,UA、hs-CRP含量明显增加[UA（359.97±32.09）mmol/L：（383.32±39.31）mmol/L∶（420.81±36.47）mmol/L,hs-CRP（4.06±1.02）mg/L∶（6.36±0.78）mg/L∶（8.10±0.64）mg/L,P〈0.05~〈0.01],UA、hs-CRP水平与病变积分呈正相关（r=0.857,P〈0.001;r=0.915,P〈0.05）。结论：尿酸、高敏C反应蛋白含量与冠心病病变程度成正相关,是冠心病的危险因素。     

心血管内科门诊戒烟服务效果分析与简化管理流程探讨

目的:评估强化门诊戒烟,随访有冠心病的吸烟患者戒烟效果以及临床预后的影响。方法:入选在我院心脏中心门诊就诊并确诊有冠心病的吸烟患者140例,按1∶1随机分为强化戒烟门诊随访组(随访组)70例,和常规治疗组(常规组)70例,分别进行不同干预措施。于6个月后比较2组的戒烟情况、戒烟误区、心血管事件率、门诊医疗费用和生活质量。结果:基线时2组患者的年龄、性别、伴发疾病、每日平均吸烟量、药物使用率差异均无统计学意义(P>0.05)。随访统计时,随访组的戒烟率高于常规组(34.29%:5.71%,P<0.01)。同时,2组合计的成功戒烟者与戒烟失败者戒烟前每日吸烟支数差异无统计学意义(13.42比13.39,P>0.05);总心血管事件率低于常规组(21.43%比47.14%,P<0.01);门诊医疗费用明显低于常规组(3 789.34元比4 984.25元,P<0.01);参考(MYO)健康状况调查问卷,生活质量各项评分均明显高于常规组(P<0.01)。结论:强化门诊戒烟随访可以明显提高患有冠心病吸烟患者的戒烟率和生活质量,降低医疗费用。     

Correlation between serum Dickkopf-1 (DKK1) levels and coronary artery stenosis

Background and aimsTo study the correlation between the level of serum Dickkopf-1 (DKK1) and the degree of coronary artery stenosis in patients with coronary atherosclerotic heart disease.Methods and resultsIn 2018, general data and biochemical indexes of 311 patients who underwent coronary angiography were recorded. Before procedure, arterial blood was drawn and the concentrations of DKK1, retinol binding protein 4 (RBP4), plasminogen activator inhibitor (PAI-1) were measured. Based on coronary angiography results, subjects were divided into a coronary heart disease (CHD) group; and a non-coronary heart disease (non-CHD)group. The CHD group was divided into three subgroups: the low Gensini score; the middle Gensini score; and the high Gensini score subgroups. Compared with those of the non-CHD group, DKK1, RBP4 and PAI-1 of the CHD group were significantly higher, while the OC was lower.DKK1,RBP4 and PAI-1 levels of the middle and high Gensini subgroups were significantly higher, compared with that of the low Gensini subgroup. Differences between osteocalcin (OC), beta-isomerized C-terminal telopeptidase (β-CTX), and 25(OH)₂D₃ of the three subgroups were not significant.Correlation between DKK1 and the inflammatory factors, RBP4 and PAI-1, was positive. Correlation between DKK1 and β - CTX, 25(OH)₂D₃ and OC was not significant. DKK1 was a risk factor for CHD. The degree of coronary artery stenosis was related to DKK1 concentration.ConclusionsSerum DKK1 levels in coronary heart disease patients were significantly higher, and positively correlated with the degree of coronary artery stenosis. DKK1 level is an independent risk factor for coronary heart disease.     

吸烟与男性早发冠心病的临床病因学的相关性研究

目的探讨吸烟与男性早发冠心病（PCAD）的关系。方法纳入270例经冠状动脉造影确诊为PCAD患者,其中男性组158例和女性组112例,对两组常见心血管危险因素（吸烟史、高血压、糖尿病、早发冠心病家族史、血脂异常等）进行分析。结果PCAD患者男性组和女性组平均年龄比较差异有统计学意义（P〈0．01）,男性组吸烟比例显著高于女性组,差异有统计学意义（P〈0．01）。两组间高血压、糖尿病、PCAD家族史无差异,但男性HDL-C（mg／d1）显著低于女性,差异有统计学意义（P〈0．01）。男性PCAD与吸烟呈正相关（OR=153．82,P〈0．01）,与HDL-C呈负相关（OR=0．95,P〈0．01）。结论男性PCAD的发病年龄早于女性,且与男性的吸烟和低HDL-C密切相关。     

血清尿酸含量与冠心病的相关性研究

目的：研究血清尿酸（SUA）含量与冠状动脉病变程度的关系。方法：选择2006年10月~2008年10月在我科住院并行冠状动脉造影的患者205例。根据冠状动脉造影结果分为CHD组154例和非CHD组51例,比较两组间有关指标的差别。根据SUA水平CHD组又被分为高尿酸组（96例）和正常尿酸组（58例）两个亚组,分析SUA水平与冠脉病变程度的关系。根据CHD病变血管支数分为单支、双支、多支病变三个亚组,比较三亚组间SUA水平。结果：（1）CHD组患者的SUA水平明显高于非CHD组[（486.94±162.96）μmol/L∶（305.69±99.58）μmol/L,P〈0.05];（2）高尿酸血症的检出率为54.1%,其中CHD组的尿酸异常率为62.34%（96/154）,明显高于非CHD组的尿酸异常率[29.41%（15/51）,P〈0.05];（3）SUA水平与性别有关,与收缩压、甘油三酯（TG）呈正相关,与高密度脂蛋白（HDL）呈负相关,r分别为0.339,0.244,0.156,-0.102,P〈0.05;（4）单支、双支、多支病变三个亚组的SUA水平分别为（387.07±100.14）μmol/L,（474.43±133.62）μmol/L,（581.30±180.21）μmol/L。SUA水平随着冠脉病变血管支数的增加而明显升高,P均〈0.01。三亚组的冠脉狭窄积分分别为（6.93±4.48）分,（16.54±11.13）分,（33.67±17.85）分,两两比较有显著差异（P均〈0.01）;（5）Logistic回归分析显示,年龄、SUA、低HDL为CHD的危险因素,OR值分别为1.102,1.012,0.397。结论：（1）血尿酸水平与性别有关,与收缩压和甘油三酯呈正相关,与高密度脂蛋白呈负相关;（2）血尿酸水平随着冠状动脉病变程度的加重而逐渐增加,是反映冠心病严重程度的一种重要生化指标;（3）在冠心病的防治中,除控制传统危险因素外,对高尿酸血症也不容忽视。